ROC curve analysis combining plasma levels of the three miRNAs to distinguish advanced cancer from benign disease groups. (A) Plasma levels of miR-34a, miR-150, and miR-923 discriminate polyp samples (n = 20) from advanced cancer (stage III/IV) samples (n = 14) individually; AUC = 0.796, 0.825, and 0.746 respectively. Combining markers miR-34a and miR-150 increases the AUC to 0.904. miR-923 expression does not improve the fit of the model and thus is not included in the combination. (B) Plasma levels of miR-150 and miR-923 discriminate adenoma samples (n = 20) from advanced cancer (stage III/IV) samples (n = 14) individually; AUC = 0.875 and 0.732 respectively. Combining these markers does not improve the fit of the model, thus miR-150 alone distinguishes adenoma samples from advanced cancer samples with an AUC of 0.875.